Dermatology

Year-long treatment with the biologic resulted in significant improvements in patient perception of well-being and treatment effect.

Investigators collected data from 5 focus groups of community-based pediatricians to address ongoing concerns on the treatment of atopic dermatitis in this pediatric population.

Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.

Investigators report that the skin condition mediated the association between a a interleukin-4 receptor agonist variant and food allergy.

Investigators report that 21.9% of all participants with allergic contact dermatitis had 1 or more currently relevant reactions to a supplemental allergen/substance.

Investigators wrote that the phenomena can be used to evaluated clinical features of the disease, resulting in more precise therapy recommendations.

By identifying 22 key parameters in study designs, investigators hope to establish a standardized approach for analyzing moderate-to-severe atopic dermatitis trial results.

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

Investigators noted the treatment method was well tolerated in patients who could not safely use oral cyclosporine.

Investigators suggested the prevention of exposure during pregnancy could help control atopic dermatitis and other potential allergies in pediatric populations.

The instrument’s score was compared favorably to the Dermatology Life Quality Index and Vitiligo Impact Patient score.

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

Though high-dose ultraviolet therapy was also effective, investigators were concerned with the potential long-term adverse events.

This represents the first biologic to show positive phase 3 results in prurigo nodularis.

Investigators believe the new instrument could be generalized to other chronic inflammatory skin diseases in future studies.

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.

Investigators call the combination of intralesional corticosteroid injections and narrow-band ultraviolet B light to be “effective, simple, and relatively safe”.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

Investigators believe that pediatric patients can gain the most from a combination of interventions, though larger studies are needed to confirm the data.

Dr. Maguiness speaks of new forms of tinea capitis not traditionally seen in the United States, as well as common practices shared between parents and clinicians for the management of several hair and nail disorders.

Dr. De Keyser highlights the success of biologics such as omalizumab and dupilumab in the treatment of asthma and atopic dermatitis in pediatric populations.

Investigators believe the reduction of DIF usage could result in cost reductions without compromising patient care.